Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)

Detalles Bibliográficos
Main Authors: Dinardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Chen, C, Lord-Bessen, J, Yu, P, Shi, L, Guo, S, Bluemmert, I, Yu, X, Hasan, M, Martin Regueira, P, De Botton, S
Formato: Journal article
Idioma:English
Publicado: American Society of Clinical Oncology 2022

Títulos similares

Títulos similares